Key result
Chronic intravenous dobutamine compared with milrinone showed no significant difference in all-cause mortality among patients with stage D heart failure (adjusted HR 0.99; 95% CI 0.5-1.97; P=0.98).
Why the study?
Does chronic intravenous dobutamine compared with milrinone improve mortality in inotrope-dependent outpatients with stage D heart failure?
Cohort (n=112)
No
Does chronic intravenous dobutamine compared with milrinone improve mortality in inotrope-dependent outpatients with stage D heart failure?
Effect estimate: HR 0.99 (95% CI 0.5 to 1.97)
p-value: p=0.98
In outpatients with stage D heart failure dependent on inotropes, there is no significant difference in mortality between chronic dobutamine and milrinone infusions.
No takes yet. Share an insight, caveat, or question.
No mortality difference should yet guide inotrope selection in stage D heart failure; leaves open randomized comparison of dobutamine versus milrinone.
Gorodeski et al. (2009) conducted a cohort in Stage D heart failure (n=112). Dobutamine vs. Milrinone was evaluated on All-cause mortality (HR 0.99, 95% CI 0.5 to 1.97, p=0.98). Chronic intravenous dobutamine compared with milrinone showed no significant difference in all-cause mortality among patients with stage D heart failure (adjusted HR 0.99; 95% CI 0.5-1.97; P=0.98).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: